Prof. MUDr. Romana Ryšavá, CSc.
Klinika nefrologie 1. LF UK a Všeobecné fakultní nemocnice v Praze
Prof. MUDr. Romana Ryšavá, CSc. se narodila v roce 1967 v Lounech. V roce 1992 absolvovala 1.LF UK Praha, fakultu všeobecného lékařství. Hned po promoci pracovala necelý rok na onkologickém oddělení Fakultní Thomayerovy nemocnice. Poté přešla do Všeobecné fakultní nemocnice v Praze na I. interní kliniku, kde pracovala na nefrologickém oddělení jako sekundární lékařka. V roce 1999 se stala odbornou asistentkou pro obor nefrologie 1. LF UK Praha, kde působí dosud jako profesorka. Nadále pracuje na Klinice nefrologie VFN ve funkci vedoucí lékařky oddělení a je zástupkyní přednosty pro zdravotnickou činnost. V roce 1995 složila atestaci I.stupně z vnitřního lékařství, v roce 1999 atestaci z vnitřního lékařství II. stupně a v roce 2001 atestaci nefrologickou. V roce 2005 se stala docentkou a od roku 2013 je jměnována profesorkou 1. LF UK pro obor vnitřní lékařství, Významným způsobem se podílí i na postgraduální výuce v oboru nefrologie.
Od počátku svého působení v nefrologii se intenzivně věnuje problematice amyloidózy a postižení ledvin, což je téma, které bylo řadu let opomíjeno. Na toto téma publikovala řadu prací a přednesla nespočet přednášek. Amyloidóza se stala i tématem její kandidátské disertační práce, která měla název „Význam amyloidových prekurzorů a některých cytokinů v diagnostice amyloidózy ledvin“.
Prof. MUDr. Romana Ryšavá, CSc. je autorkou či spoluautorkou více jak 70 originálních prací a přehledových článků, z nichž řada byla publikována v uznávaných impaktovaných časopisech. Citační index jejích prací je přes 200. V roce 1998 a 1999 byla tato její publikační činnost oceněna cenou Klubu mladých nefrologů za nejlepší publikaci v roce 1997 a 1998. Je také autorkou řady kapitol v učebnicích pro mediky a v monografiích, které se týkají nefrologické problematiky či problematiky amyloidózy.
Prof. MUDr. Romana Ryšavá, CSc. je členkou řady odborných společností - European Dialysis and Transplant Association (ERA-EDTA), International Society of Nephrology (ISN), International Society of Amyloidosis (ISA) a České nefrologické společnosti (ČNS). Od roku 2004 pracuje ve výboru ČNS, kde zastávala nejprve post pokladníka, v letech 2006-2008 post 1. místopředsedkyně, 2008-2010 předsedkyně a 2010-2012 byla 2.místopředsedkyní. V současném výboru působí jako koordinátorka pro jednání se státními institucemi. Během svého působení ve výboru byla presidentkou či hlavní pořadatelkou řady odborných akcí či kongresů.
Je členkou redakční rady řady časopisů (Postgraduální nefrologie, Medicína pro praxi, Aktuality v nefrologii, Kidney and Blood Pressure Research) a recenzentkou odborných publikací, doktorských prací či grantů. Od roku 2017 je předsedkyní redakční rady časopisu Postgraduální nefrologie. Z dalších aktivit je třeba jmenovat členství v akreditační komisi MZd pro obor nefrologie, členství v atestační komisi pro obor nefrologie. Je také hlavní řešitelkou či spoluřešitelkou několika grantových projektů či výzkumných záměrů a klinických studií.
Prof. MUDr. Romana Ryšavá, CSc. je autorem těchto článků v časopise Postgraduální nefrologie:
Kaufeld JK, Kühne L, Schönermarck U, et al. Features of postpartum hemorrhage‑associated thrombotic microangiopathy and role of short‑term complement inhibition. Kidney Int Rep 2024;9:919–928.
Hayward G, Mort S, Hay A, et al. D‑mannose for prevention of recurrent urinary tract infection among women: a randomized clinical trial. JAMA Intern Med 2024 Apr 8:e240264. doi: 10.1001/jamainternmed.2024.0264. Online ahead of print.
Mathur M, Barratt J, Chacko B, et al. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. N Engl J Med 2024;390:20–31.
Barratt J, Lafayette R, Kristensen J, et al.; for the NefIgArd Trial Investigators. Results from part A of the multi‑center, double‑blind, randomized, placebo‑controlled NefIgArd trial, which evaluated targeted‑release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 2023;103:391–402.
Ponte C, Grayson PC, Robson JC, et al; DCVAS Study Group. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis 2022;81:1647–1653. Arthritis Rheumatol 2022 Nov 8. doi: 10.1002/art.42325. Epub ahead of print.
Grayson PC, Ponte C, Suppiah R, et al; DCVAS Study Group. 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis.
Ann Rheum Dis 2022;81:1654–1660. Arthritis Rheumatol 2022 Nov 8. doi: 10.1002/art.42324. Epub ahead of print. PMID: 36349501.
Hummel A, Oniszczuk J, Kervella D, et al. Idiopathic nephrotic syndrome relapse following COVID‑19 vaccination: a series of 25 cases. Clin Kidney J 2022;15:1574–1582.
Sikora J, Kmochová T, Mušálková D, et al. A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. Kidney Int 2022;101:349–359.
Clarke CL, Prendecki M, Dhutia A, et al. Longevity of SARS‑CoV‑2 immune responses in hemodialysis patients and protection against reinfection. Kidney Int 2021;99:1470–1477.
De Vriese AS, Caluwé R, Van Der Meersch H, et al. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. J Am Soc Nephrol 2021 Mar 22:ASN.2020111566. doi: 10.1681/ASN.2020111566
Ozturk S, Turgutalp K, Arici M, et al. Mortality analysis of COVID‑19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrol Dial Transplant 2020;35:2083–2095.
Furie R, Rovin BH, Houssiau F, et al. Two‑Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med 2020;383:1117–1128.
Royal V, Leung N, Troyanov S, et al. Clinicopathological predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood 2020;135:1833–1846.
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Ertyhematosus.
Arthritis Rheumatol 2019 Aug 6. doi: 10.1002/art.40930, Ann Rheum Dis 2019;78:1151–1159.
Hutchison CA, Cockwell P, Moroz V, et al. High cutoff versus high‑flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib‑based chemotherapy (EuLITE): a phase 2 randomized controlled trial.
Lancet Haematol 2019;6:e217–e228.
Fernandez‑Juarez G, Perez JV, Caravaca‑Fontán F, et al.; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis.
Clin J Am Soc Nephrol 2018;13:1851–1858.
Calderon‑Margalit R, Golan E, Twig G, et al.
History of Childhood Kidney Disease and Risk of Adult End‑Stage Renal Disease. N Engl J Med 2018;378:428–438.
Toth PP, Dwyer JP, Cannon CP, et al.
Efficacy nad safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 2018;93:1397–1408.
Gaggl M, Aigner C, Csuka D, et al.
Bridoux F, Carron PL, Pegourie B, et al.
Sinha A, Gupta A, Kalaivani M, et al.
Fellström BC, Barratt J, Cook H, et al.
Targeted‑release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double‑blind, randomised, placebo‑controlled phase 2b trial. Lancet 2017;389:2117–2127.
Blanchard A, Bockenhauer D, Bolignano D, et al. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Kidney International 2017;91:24–33.
Xie Y, Bowe B, Li T, et al.
Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol 2016;27:3153–3163.
Leung N, Kumar SK, Glavey SV, et al.
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis ungergoing autologous stem cell transplantation. Nephrol Dial Transplant 2016;31:1284–1289.
Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015;88:905–914.
Thompson S, James M, Wiebe N, et al.; Alberta Kidney Disease Network. Cause of death in patients with reduced kidney function. J Am Soc Nephrol 2015;26:2504–2511.
Navaneethan S, Schold J, Arrigain S, et al. Cause‑specific deaths in non‑dialysis dependent chronic kidney disease. J Am Soc Nephrol 2015;26: 2512–2520.
Boils CL, Nasr SH, Walker PD, Couser WG, Larsen CP. Update on endocarditis‑associated glomerulonephritis. Kidney Int 2015;87:1241–1249.
Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014;129:1196–1203.
Lewis JB, Sika M, Koury JM, et al. Ferric citrate controls phosphorus and deliveres iron in patients on dialysis. J Am Soc Nephrol 2014; 26: e‑pub Jul 24. ASN.2014020212
Zakharov S, Pelclova D, Navratil T, et al. Intermittent hemodialysis is superior to continuous veno‑venous hemodialysis/hemodiafiltraion to eliminate methanol and formate during treatment for methanol poisoning. Kidney Int 2014;86:199–207.
Tradiční čínská medicína v léčbě membranózní nefropatie: šarlatánství či vědecky podložené výsledky?
Chen Y, Deng Y, Ni Z, et al. Efficacy and safety of traditional Chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial. Am J Kidney Dis 2013;62:1068–1076.
Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic‑uremic syndrome. N Eng J Med 2013;368:2169‑2181.
Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, Webster AC. Induction and maintenance treatment of proliferative lupus nephritis: a meta‑analysis of randomized controlled trials. Am J Kidney Dis 2013;61:74–87.
Macdougall IC, Provenzano R, Sharma A et al. for the PEARL Study Groups. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013;368:320–332.
KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int 2012;2(Suppl 4):279–336.
Hemmelgarn BR, James MT, Manns BJ, et al. Rates of treated and untreated kidney failure in older vs. younger adults. JAMA 2012;307:2507–2515.
Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, Wright JT Jr, Barzilay JI, Brown CD, Colon PJ Sr, Fine LJ, Grimm RH Jr, Gupta AK, Baimbridge C, Haywood LJ, Henriquez MA, Ilamaythi E, Oparil S, Preston R; for the ALLHAT Collaborative Research Group. Long‑term renal and cardiovascular outcomes in Antihypertensive and Lipid‑Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol 2012;7:989–1002.
Kim JK, Kim JH, Lee SC, et al. Clinical features and outcomes of IgA nephropathy with nephrotic syndrome. Clin J Am Soc Nephrol 2012;7:427–436.
Gross O, Licht C, Anders HJ, et al. Early angiotensin‑converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 2012;81:494–501.
Frank Ch, Werber D, Cramer JP, et al., for the HUS Investigation Team. Epidemic profile of Shiga‑toxin‑producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011;365:1771–1780.
Cruzado JM, Poveda R, Ibernón M, et al. Low‑dose sirolimus combined with angiotensin‑converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy. Nephol Dial Transplant 2011;26:3596–3602.
Vaglio A, Palmisano A, Alberici F et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open‑label randomised controlled trial. Lancet 2011;378:338–346.
Molnar MZ, Mehrotra R, Duong U, Kovesdy CP, Kalantar‑Zadeh K. Association of hemoglobin and survival in peritoneal dialysis patients. Clin J Am Soc Nephrol 2011;6:1973–1981.
Sayyed SG, Ryu M, Kulkarni OP, et al. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int 2011;80:68–78.
Herrmann SMS, Gertz MA, Stegall MD, et al. Long‑term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant 2011;26:2032–2036.
Szummer K, Lundman P, Jacobson SH, Schön S, Lindbäck J, Stenestrand U, Wallentin L, Jernberg T, for SWEDEHEART. Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney Int 2011;79:997–1004.
Stanescu HC, Arcos‑Burgos M, Medlar A, et al. Risk HLA‑DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011;364:616–626.
Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo‑controlled, phase 3 trial. Lancet 2011;377:721–731.
Carrera F, Lok CE, de Francisco A, et al., on behalf of the PATRONUS Investigators. Maintenance treatment of renal anaemia in hemodialysis patients with methoxy polyethylene glycol‑epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010;25:4009–4017.
Symplicity HTN‑2 Investigators. Renal sympathetic denervation in patients with treatment‑resistant hypertension (The Symplicity HTN‑2 Trial): a randomised controlled trial. Lancet 2010;376:1903–1909.
Eckardt KU, Kim J, Kronenberg F, et al. Hemoglobin variability does not predict mortality in European hemodialysis patients. JASN 2010;21:1765–1775
Srai SK, Chung B, Marks J, et al. Erythropoietin regulates intestinal iron absorption in a rat model of chronic renal failure. Kidney Int 2010;78:660–667.
Agarwal R, Light RP. Intradialytic hypertension is a marker of volume excess. Nephrol Dial Transplant 2010;25:3355–3361.
Jalal DI, Smits G, Johnson RJ, Chonchol M. Increased fructose associates with elevated blood pressure. J Am Soc Nephrol 2010;21:1543–1549.
Sinico RA, Cavazzana I, Nuzzo M, et al. Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin JASN 2010;65:1211–1217.
Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, Harris A, Johnson DW, Kesselhut J, Li JJ, Luxton G, Pilmore A, Tiller DJ, Harris DC, Pollock CA; the IDEAL Study. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363:609–619.
Korgaonkar S, Tilea A, Gillespie BW, Kiser M, Eisele G, Finkelstein F, Kotanko P, Pitt B, Saran R. Serum potassium and outcomes in CKD: Insights from the RRI‑CKD Cohort Study. Clin J Am Soc Nephrol 2010;5:762–769.
Ruilope LM, Dukat A, Böhm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual‑acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255–1266.
Tang SCW, Tang AWC, Wong SSH, Leung JCK, Ho YW, Lai KN. Long‑term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010;77:543–549.
Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20‑year experience from a single centre. Nephrol Dial Transplant 2010;25(2):419–426.
Piccoli GB, Conijn A, Consiglio V, Vasario E, Attini R, Deagostini MC, Bontempo S, Todros T. Pregnancy in dialysis patients: is the evidence strong enough to lead us to change our counseling policy? Clin J Am Soc Nephrol 2010;5:62‑71. 2009;4:1974–1979.
Fabris A, Bernich P, Abaterusso C, et al. Bone disease in medullary sponge kidney and effect of potassium citrate treatment. Clin J Am Soc Nephrol 2009;4:1974–1979.
Marcelli D, Marelli C, Richards N. Influenza A(H1N1)v pandemic in the dialysis population: first wave results from an international survey. Nephrol Dial Transplant 2009;12:3566–3572.
Maripuri S, Grande JP, Osborn TG, Fervenza FC, Matteson EL, Donadio JV, Hogan MC. Renal involvement in primary Sjögren’s syndrome: a clinicopathologic study. Clin J Am Soc Nephrol 2009;4:1423–1431.
Cattran DC, Coppo R, Cook HT, et al., and Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534–545.
Sanna‑Cherchi S, Ravani P, Corbani V, Parodi S, Haupt R, Piaggio G, Innocenti ML, Somenzi D, Trivelli A, Caridi G, Izzi C, Scolari F, Mattioli G, Allegri L, Ghiggeri GM. Renal outcome in patients with congenital anomalies of the kidney and urinary tract. Kidney Int 2009;76:528–533.
Rule AD, Bergstralh EJ, Melton LJ 3rd, Li X, Weaver AL, Lieske JC. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 2009;4:804–411.
Pizzarelli F, Lauretani F, Bandinelli S, Windham GB, Corsi AM, Giannelli SV, Ferrucci L, Guralnik JM. Predictivity of survival according to different equations for estimating renal function in community-dwelling elderly subjects. Nephrol Dial Transplant. 2009;24:1197–205.
Bouchard J, Madore F. Role of citrate and other methods of anticoagulation in patiens with severe liver failure requiring continuous renal replacement therapy. Nephrol Dial Transplant Plus 2009;2:11–19.
Lins RL, Elseviers MM, Van der Niepen P, Hoste E, Malbrain ML, Damas P, Devriendt J, for the SHARF investigators. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of randomized clinical trial. Nephrol Dial Transpl2009; 24:512–518.
Seliger SL, Zhan M, Hsu VD, Walker LD, Fink JC. Chronic kidney disease adversely influences patient safety. J Am Soc Nephrol 2008;19:2414–2419.
Sugimoto M, Sakai K, Kita M, Imanishi J, Yamaoka Y. Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney Int 2009;75:96–103.
Vizjak A, Ferluga D, Rožič M, Hvala A, Lindin J, Levart TK, Jurčič V, Jennette JC. Pathology, clinical presentation and outcomes of C1q nephropathy. J Am Soc Nephrol 2008;19:2237–2244.
Holubek WJ, Hoffman RS, Goldfarb DS, Nelson LS. Use of hemodialysis and hemoperfusion in poisoned patients. Kidney Int 2008;74:1327–1334.
Harada K, Akai Y, Yamaguchi Y, Kimura K, Nishitani Y, Nakatani K, Iwano M, Saito Y. Prediction of corticosteroid responsiveness based on fibroblast-specific protein 1 (FSP1) in patients with IgA nephropathy. Nephrol Dial Transplant 2008;23:3152–3159.
Winthrop KL, Nyendak M, Calvet H, et al. Interferon-gama release assays for diagnosing Mycobacterium tuberculosis infection in renal dialysis patients. Clin J Am Soc Nephrol 2008;3:1357–1363.
Ishani A, Blackell T, Jamal SA, et al. for the MORE Investigators. The effect of raloxifen treatment in postmenopausal women with CKD. J Am Soc Nephrol 2008;19:1430–1438.
Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008;73:1282–1288.
Ninomiya T, Peckovic V, Gallagher M, et al.; for the PROGRESS Collaborative Group. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney Int 2008;73:963–970.
Wattanakit K, Cushman M, Stehman‑Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008;19:135–140.
Léčba mikroalbuminurie u nemocných s hypertenzí a kardiovaskulárním rizikem: výsledky studie IMPROVE
Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, deChamplain J, Weber MA, Raz I. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE study. Kidney Int 2007;72: 879–885.
Éthier J, Bragg-Gresham JL, Piera L, Akizawa T, Asano Y, Mason N, Gillespie BW, Young EW. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2007;50:602–611.
Swaminathan S, Shah SV. New insights into nephrogenic systemis fibrosis. J Am Soc Nephrol 2007;18:2636–2643.
Prescott GJ, Metcalfe W, Baharani J, Khan IH, Simpson K, Smith WCS, MacLeod AM. A prospective national study of acute renal failure treated with RRT: inci-dence, aetiology and outcomes. Nephrol Dial Transplant 2007; 22:2513–2519.
Gera M, Griffi n MD, Specks U, Leung N, Stegall MD, Fervenza FC. Recurrence of ANCA-associted vasculitis following renal transplantation in the modern era of immunosuppression. Kidney Inter 2007;71:1296–1301.
Dember LM, Hawkins PN, Hazenberg BPC, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puechal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M for the Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356:2349–2360.
Yu Ch, Gong R, Rifai A, Tolbert EM, Dworkin LD. Long‑term, high‑dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. J Am Soc Nephrol 2007;18:750–759.
Macdougall IC, Temple RM, Kwan JTC, on behalf of the EPO‑GBR‑2 Study Group. Is early treatment of anaemia wih epoetin‑a beneficial to pre‑dialysis chronic kidney disease patients? Results of multicentre, open‑label, prospective, randomized, comparative group trial. Nephrol Dial Transplant 2007;22:784–793.
Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar‑ZadehK. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007;18:293–303.
Thibaudin D, Thibaudin L, Berthhoux P, Mariat C, deFilippis JP, Laureat B, Alamartine E, Berthoux F. TNFA2 and d2 alleles of tumor necrosis factor alpha gene polymorphism are associated with onset/occurence of idiopathic membranous nephropathy. Kidney Int 2007;71:1–7.
Cho KC, Himmelfarb J, Paganini E, Ikizler TA, Soroko SH, Mehta RL, Chertow GM. Survival by dialysis modality in critically ill patients with acute kidney injury. J Am Soc Nephrol 2006;17:3132–3138.
Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int 2006;70:1495–1502.
Ludvigsson JF, Montgomery SM, Olén O, Ekbom A, Ludvigsson J, Fored M. : Coeliac disease and risk of renal disease – a general population cohort study. Nephrol Dial Transplant 2006; 21:1809-1815.
Yasuda K, Kasuga H, Aoyama T, Takahashi H, Toriyama T, Kawade Y, Iwashima S, Yamada S, Kawahara H, Maruyama S, Yuzawa Y, Ishii H, Murohara T, Matsuo S.: Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients. J Am Soc Nephrol 2006;17:2322–2332.
Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int 2006;69:1934–1938.
Moroni G, Gallelli B, Quaglini S, Banfi G, Rivolta E, Messa P, Ponticelli C.: Withdrawal of therapy in patiens with proliferative lupus nephritis: long-term followup. Nephrol Dial Transplant 2006;21:1541–1548.
Ergün I, Keven K, Uruc I, et al. The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 2006;21:697–700.
Fujii Y, Khoshnoodi J, Takenaka H, et al. The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases. Kidney Int 2006;69:1350–1359.
Gertz AG, Leung N, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement. Kidney Int 2005;68:1464-1471.
Javaid B, Quigg RJ. Treatment of glomerulonephritis: will we ever have options other than steroids and cytotoxics? Kidney Int 2005;67 :1692-1703.
Chan T-M, Tse K-C, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076–1084.